nach oben

Erschienen in:

12.08.2021 | Research Article

GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[¹⁸F]F-FDG-PET

verfasst von: Martina Capozza, Annasofia Anemone, Chetan Dhakan, Melania Della Peruta, Martina Bracesco, Sara Zullino, Daisy Villano, Enzo Terreno, Dario Livio Longo, Silvio Aime

Erschienen in: Molecular Imaging and Biology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Triple-negative breast cancer (TNBC) patients have usually poor outcome after chemotherapy and early prediction of therapeutic response would be helpful. [¹⁸F]F-FDG-PET/CT acquisitions are often carried out to monitor variation in metabolic activity associated with response to the therapy, despite moderate accuracy and radiation exposure limit its application. The glucoCEST technique relies on the use of unlabelled D-glucose to assess glucose uptake with conventional MRI scanners and is currently under active investigations at clinical level. This work aims at validating the potential of MRI-glucoCEST in monitoring the therapeutic responses in a TNBC tumor murine model.

Procedures

Breast tumor (4T1)–bearing mice were treated with doxorubicin or dichloroacetate for 1 week. PET/CT with [¹⁸F]F-FDG and MRI-glucoCEST were performed at baseline and after 3 cycles of treatment. Metabolic changes measured with [¹⁸F]F-FDG-PET and glucoCEST were compared and evaluated with changes in tumor volumes.

Results

Doxorubicin-treated mice showed a significant decrease in tumor growth when compared to the control group. GlucoCEST imaging provided metabolic response after three cycles of treatment. Conversely, no variations were detected in [¹⁸F]F-FDG uptake. Dichloroacetate-treated mice did not show any decrease either in tumor volume or in tumor metabolic activity as assessed by both glucoCEST and [¹⁸F]F-FDG-PET.

Conclusions

Metabolic changes during doxorubicin treatment can be predicted by glucoCEST imaging that appears more sensitive than [¹⁸F]F-FDG-PET in reporting on therapeutic response. These findings support the view that glucoCEST may be a sensitive technique for monitoring metabolic response, but future studies are needed to explore the accuracy of this approach in other tumor types and treatments.

Nur mit Berechtigung zugänglich

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef

Pantel AR, Ackerman D, Lee SC, Mankoff DA, Gade TP (2018) Imaging cancer metabolism: underlying biology and emerging strategies. J Nucl Med 59:1340–1349PubMedPubMedCentral

Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683–693PubMed

Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11:2101–2111PubMed

Takada K, Toyokawa G, Yoneshima Y et al (2019) F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. Sci Rep 9:13362PubMedPubMedCentral

Schwarz-Dose J, Untch M, Tiling R et al (2009) Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 27:535–541PubMed

García Vicente AM, Cruz Mora M, León Martín AA et al (2014) Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer. Tumour Biol 35:11613–11620PubMed

Avril S, Muzic RF, Plecha D, Traughber BJ, Vinayak S, Avril N (2016) 18F-FDG PET/CT for monitoring of treatment response in breast cancer. J Nucl Med 57(Suppl 1):34S-39SPubMed

Wang Y, Zhang C, Liu J, Huang G (2012) Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat 131:357–369PubMed

10.

Zhang Q, Gao X, Wei G, Qiu C, Qu H, Zhou X (2019) Prognostic value of MTV, SUVmax and the T/N Ratio of PET/CT in patients with glioma: a systematic review and meta-analysis. J Cancer 10:1707–1716PubMedPubMedCentral

11.

Cheng X, Li Y, Liu B, Xu Z, Bao L, Wang J (2012) 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Acta Radiol 53:615–627PubMed

12.

Consolino L, Anemone A, Capozza M et al (2020) Non-invasive investigation of tumor metabolism and acidosis by MRI-CEST imaging. Front Oncol 10:161PubMedPubMedCentral

13.

Goldenberg JM, Pagel MD (2019) Assessments of tumor metabolism with CEST MRI. NMR Biomed 32:e3943PubMed

14.

Anemone A, Consolino L, Arena F, Capozza M, Longo DL (2019) Imaging tumor acidosis: a survey of the available techniques for mapping in vivo tumor pH. Cancer Metastasis Rev 38:25–49PubMedPubMedCentral

15.

Liu G, Song X, Chan KW, McMahon MT (2013) Nuts and bolts of chemical exchange saturation transfer MRI. NMR Biomed 26:810–828PubMedPubMedCentral

16.

Nasrallah FA, Pagès G, Kuchel PW, Golay X, Chuang KH (2013) Imaging brain deoxyglucose uptake and metabolism by glucoCEST MRI. J Cereb Blood Flow Metab 33:1270–1278PubMedPubMedCentral

17.

Xu X, Chan KW, Knutsson L et al (2015) Dynamic glucose enhanced (DGE) MRI for combined imaging of blood-brain barrier break down and increased blood volume in brain cancer. Magn Reson Med 74:1556–1563PubMedPubMedCentral

18.

Chan KW, McMahon MT, Kato Y et al (2012) Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer. Magn Reson Med 68:1764–1773PubMedPubMedCentral

19.

Xu X, Yadav NN, Knutsson L et al (2015) Dynamic glucose-enhanced (DGE) MRI: translation to human scanning and first results in glioma patients. Tomography 1:105–114PubMedPubMedCentral

20.

Wang J, Weygand J, Hwang KP et al (2016) Magnetic resonance imaging of glucose uptake and metabolism in patients with head and neck cancer. Sci Rep 6:30618PubMedPubMedCentral

21.

Paech D, Schuenke P, Koehler C et al (2017) T1ρ-weighted dynamic glucose-enhanced MR imaging in the human brain. Radiology 285:914–922PubMed

22.

Walker-Samuel S, Ramasawmy R, Torrealdea F et al (2013) In vivo imaging of glucose uptake and metabolism in tumors. Nat Med 19:1067–1072PubMedPubMedCentral

23.

Rivlin M, Horev J, Tsarfaty I, Navon G (2013) Molecular imaging of tumors and metastases using chemical exchange saturation transfer (CEST) MRI. Sci Rep 3:3045PubMedPubMedCentral

24.

Rivlin M, Navon G (2018) CEST MRI of 3-O-methyl-D-glucose on different breast cancer models. Magn Reson Med 79:1061–1069PubMed

25.

Sehgal AA, Li Y, Lal B et al (2019) CEST MRI of 3-O-methyl-D-glucose uptake and accumulation in brain tumors. Magn Reson Med 81:1993–2000PubMed

26.

Longo DL, Moustaghfir FZ, Zerbo A et al (2017) EXCI-CEST: exploiting pharmaceutical excipients as MRI-CEST contrast agents for tumor imaging. Int J Pharm 525:275–281PubMed

27.

Schuenke P, Paech D, Koehler C et al (2017) Fast and quantitative T1rho-weighted dynamic glucose enhanced MRI. Sci Rep 7:42093PubMedPubMedCentral

28.

Xu X, Sehgal AA, Yadav NN et al (2020) d-glucose weighted chemical exchange saturation transfer (glucoCEST)-based dynamic glucose enhanced (DGE) MRI at 3T: early experience in healthy volunteers and brain tumor patients. Magn Reson Med 84:247–262PubMed

29.

Kim M, Torrealdea F, Adeleke S et al (2019) Challenges in glucoCEST MR body imaging at 3 Tesla. Quant Imaging Med Surg 9:1628–1640PubMedPubMedCentral

30.

Zaiss M, Anemone A, Goerke S et al (2019) Quantification of hydroxyl exchange of D-glucose at physiological conditions for optimization of glucoCEST MRI at 3, 7 and 9.4 Tesla. NMR Biomed 32:e4113PubMedPubMedCentral

31.

Zhang L, Martins AF, Mai Y et al (2017) Imaging extracellular lactate in vitro and in vivo using CEST MRI and a paramagnetic shift reagent. Chemistry 23:1752–1756PubMedPubMedCentral

32.

Chirayil S, Jordan VC, Martins AF, Paranawithana N, Ratnakar SJ, Sherry AD (2021) Manganese(II)-based responsive contrast agent detects glucose-stimulated zinc secretion from the mouse pancreas and prostate by MRI. Inorg Chem 60:2168–2177PubMed

33.

Yan G, Zhang T, Dai Z et al (2016) A potential magnetic resonance imaging technique based on chemical exchange saturation transfer for in vivo gamma-aminobutyric acid imaging. PLoS One 11:e0163765PubMedPubMedCentral

34.

Paech D, Dreher C, Regnery S et al (2019) Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients. Eur Radiol 29:4957–4967PubMed

35.

Chan KW, Jiang L, Cheng M et al (2016) CEST-MRI detects metabolite levels altered by breast cancer cell aggressiveness and chemotherapy response. NMR Biomed 29:806–816PubMedPubMedCentral

36.

Jia Y, Wang C, Zheng J et al (2019) Novel nanomedicine with a chemical-exchange saturation transfer effect for breast cancer treatment in vivo. J Nanobiotechnology 17:123PubMedPubMedCentral

37.

Krikken E, Khlebnikov V, Zaiss M et al (2018) Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res 20:51PubMedPubMedCentral

38.

Longo DL, Bartoli A, Consolino L et al (2016) In vivo imaging of tumor metabolism and acidosis by combining PET and MRI-CEST pH imaging. Cancer Res 76:6463–6470PubMed

39.

Xu X, Xu J, Knutsson L et al (2019) The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma. Magn Reson Med 81:3798–3807PubMedPubMedCentral

40.

Oakman C, Viale G, Di Leo A (2010) Management of triple negative breast cancer. Breast 19:312–321PubMed

41.

Tian F, Shen G, Deng Y, Diao W, Jia Z (2017) The accuracy of (18)F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review. Eur Radiol 27:4786–4796PubMed

42.

Stacpoole PW (2017) Therapeutic targeting of the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis in cancer. J Natl Cancer Inst 109(11)

43.

Chu QS, Sangha R, Spratlin J et al (2015) A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors. Invest New Drugs 33:603–610PubMed

44.

Papageorgis P, Polydorou C, Mpekris F et al (2017) Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner. Sci Rep 7:46140PubMedPubMedCentral

45.

Anemone A, Consolino L, Conti L et al (2017) In vivo evaluation of tumour acidosis for assessing the early metabolic response and onset of resistance to dichloroacetate by using magnetic resonance pH imaging. Int J Oncol 51:498–506PubMed

46.

Longo DL, Dastru W, Digilio G et al (2011) Iopamidol as a responsive MRI-chemical exchange saturation transfer contrast agent for pH mapping of kidneys: In vivo studies in mice at 7 T. Magn Reson Med 65:202–211PubMed

47.

Avril N, Sassen S, Roylance R (2009) Response to therapy in breast cancer. J Nucl Med 50(Suppl 1):55S-63SPubMed

48.

Thorn CF, Oshiro C, Marsh S et al (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21:440–446PubMedPubMedCentral

49.

Shin HJ, Kwon HK, Lee JH et al (2015) Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53. Sci Rep 5:15798PubMedPubMedCentral

50.

Borchmann S, von Tresckow B, Engert A (2016) Current developments in the treatment of early-stage classical Hodgkin lymphoma. Curr Opin Oncol 28:377–383PubMed

51.

Meredith AM, Dass CR (2016) Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J Pharm Pharmacol 68:729–741PubMed

52.

Varghese E, Samuel SM, Líšková A, Samec M, Kubatka P, Büsselberg D (2020) Targeting glucose metabolism to overcome resistance to anticancer chemotherapy in breast cancer. Cancers 12(8):2252

53.

García-Castillo V, López-Urrutia E, Villanueva-Sánchez O et al (2017) Targeting metabolic remodeling in triple negative breast cancer in a murine model. J Cancer 8:178–189PubMedPubMedCentral

54.

Kristian A, Holtedahl JE, Torheim T et al (2017) Dynamic 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography for chemotherapy response monitoring of breast cancer xenografts. Mol Imaging Biol 19:271–279PubMed

55.

Jensen MM, Kjaer A (2015) Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies. Am J Nucl Med Mol Imaging 5:431–456PubMedPubMedCentral

56.

Aliaga A, Rousseau JA, Cadorette J et al (2007) A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol 9:144–150PubMed

57.

Goldenberg JM, Cardenas-Rodriguez J, Pagel MD (2018) Preliminary results that assess metformin treatment in a preclinical model of pancreatic cancer using simultaneous [(18)F]FDG PET and acidoCEST MRI. Mol Imaging Biol 20:575–583PubMedPubMedCentral

58.

Humbert O, Cochet A, Coudert B et al (2015) Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist 20:94–104PubMedPubMedCentral

59.

Kristian A, Nilsen LB, Røe K et al (2013) Dynamic (18) F-FDG PET for assessment of tumor physiology in two breast carcinoma xenografts. Nucl Med Mol Imaging 47:173–180PubMedPubMedCentral

60.

Michelakis ED, Webster L, Mackey JR (2008) Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99:989–994PubMedPubMedCentral

61.

Kankotia S, Stacpoole PW (2014) Dichloroacetate and cancer: new home for an orphan drug? Biochim Biophys Acta 1846:617–629PubMed

62.

Tataranni T, Piccoli C (2019) Dichloroacetate (DCA) and cancer: an overview towards clinical applications. Oxid Med Cell Longev 2019:8201079PubMedPubMedCentral

63.

Feuerecker B, Seidl C, Pirsig S, Bruchelt G, Senekowitsch-Schmidtke R (2015) DCA promotes progression of neuroblastoma tumors in nude mice. Am J Cancer Res 5:812–820PubMedPubMedCentral

64.

Neveu MA, De Preter G, Joudiou N et al (2016) Multi-modality imaging to assess metabolic response to dichloroacetate treatment in tumor models. Oncotarget 7:81741–81749PubMedPubMedCentral

65.

Park JM, Recht LD, Josan S et al (2013) Metabolic response of glioma to dichloroacetate measured in vivo by hyperpolarized (13)C magnetic resonance spectroscopic imaging. Neuro Oncol 15:433–441PubMedPubMedCentral

66.

Albatany M, Li A, Meakin S, Bartha R (2018) Dichloroacetate induced intracellular acidification in glioblastoma: in vivo detection using AACID-CEST MRI at 9.4 Tesla. J Neurooncol 136:255–262PubMed

67.

Shahriari M, Taghdisi SM, Abnous K, Ramezani M, Alibolandi M (2019) Synthesis of hyaluronic acid-based polymersomes for doxorubicin delivery to metastatic breast cancer. Int J Pharm 572:118835PubMed

68.

Lu Z, Long Y, Cun X et al (2018) A size-shrinkable nanoparticle-based combined anti-tumor and anti-inflammatory strategy for enhanced cancer therapy. Nanoscale 10:9957–9970PubMed

69.

Paech D, Radbruch A (2021) Dynamic glucose-enhanced MR imaging. Magn Reson Imaging Clin N Am 29:77–81PubMed

70.

Jin T, Mehrens H, Hendrich KS, Kim SG (2014) Mapping brain glucose uptake with chemical exchange-sensitive spin-lock magnetic resonance imaging. J Cereb Blood Flow Metab 34:1402–1410PubMedPubMedCentral

71.

Boyd PS, Breitling J, Zimmermann F et al (2020) Dynamic glucose-enhanced (DGE) MRI in the human brain at 7 T with reduced motion-induced artifacts based on quantitative R1rho mapping. Magn Reson Med 84:182–191PubMed

72.

Breitling J, Deshmane A, Goerke S et al (2019) Adaptive denoising for chemical exchange saturation transfer MR imaging. NMR Biomed 32:e4133PubMed

73.

Chen L, Cao S, Koehler RC, van Zijl PCM, Xu J (2020) High-sensitivity CEST mapping using a spatiotemporal correlation-enhanced method. Magn Reson Med 84:3342–3350PubMedPubMedCentral

74.

Romdhane F, Villano D, Irrera P, Consolino L, Longo DL (2021) Evaluation of a similarity anisotropic diffusion denoising approach for improving in vivo CEST-MRI tumor pH imaging. Magn Reson Med 85:3479–3496PubMed

75.

Nasrallah FA, Pages G, Kuchel PW, Golay X, Chuang KH (2013) Imaging brain deoxyglucose uptake and metabolism by glucoCEST MRI. J Cereb Blood Flow Metab 33:1270–1278PubMedPubMedCentral

76.

Eleftheriou A, Ravotto L, Wyss M, Warnock G, Siebert A, B. W (2019) Simultaneous glucoCEST and fiber photometryof glucose in the healthy mouse brain. Magn Reson Mater Phy 32:107–233 (ESMRMB 2019, 36th Annual Scientific Meeting, Rotterdam, NL, October 3 - October 5: Abstracts, Friday)

Titel: GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[18F]F-FDG-PET
verfasst von: Martina Capozza
Annasofia Anemone
Chetan Dhakan
Melania Della Peruta
Martina Bracesco
Sara Zullino
Daisy Villano
Enzo Terreno
Dario Livio Longo
Silvio Aime
Publikationsdatum: 12.08.2021
Verlag: Springer International Publishing
Erschienen in: Molecular Imaging and Biology / Ausgabe 1/2022
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-021-01637-6

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[¹⁸F]F-FDG-PET